The interaction of Δ9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm

Byron Jones, Paul F. Consroe, Hugh E. Laird

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In rabbits, i.v. Δ9-tetrahydrocannabinol (Δ9-THC) at 0.5 mg/kg was challenged with i.v. arecoline (0.025 mg/kg), nicotine (0.02 mg/kg) or physostigmine (PHYSO, 0.05 mg/kg), and observations were made on quantified EEG and behavior. The cholinomimetics effectively reversed the cortical and hippocampal EEG alterations induced by Δ9-THC. Arecoline and PHYSO temporarily reversed the behavioral-sedative effects of Δ9-THC whereas the combination of Δ9-THC with nicotine produced behavioral collapse preceded by behavioral disturbance.

Original languageEnglish (US)
Pages (from-to)253-259
Number of pages7
JournalEuropean Journal of Pharmacology
Volume38
Issue number2
DOIs
StatePublished - Jan 1 1976

Fingerprint

Dronabinol
Cholinergic Agents
Arecoline
Nicotine
Pharmaceutical Preparations
Electroencephalography
Physostigmine
Hypnotics and Sedatives
Rabbits

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

The interaction of Δ9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm. / Jones, Byron; Consroe, Paul F.; Laird, Hugh E.

In: European Journal of Pharmacology, Vol. 38, No. 2, 01.01.1976, p. 253-259.

Research output: Contribution to journalArticle

@article{da6d07fdf62541668c7fc87b803ef9b4,
title = "The interaction of Δ9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm",
abstract = "In rabbits, i.v. Δ9-tetrahydrocannabinol (Δ9-THC) at 0.5 mg/kg was challenged with i.v. arecoline (0.025 mg/kg), nicotine (0.02 mg/kg) or physostigmine (PHYSO, 0.05 mg/kg), and observations were made on quantified EEG and behavior. The cholinomimetics effectively reversed the cortical and hippocampal EEG alterations induced by Δ9-THC. Arecoline and PHYSO temporarily reversed the behavioral-sedative effects of Δ9-THC whereas the combination of Δ9-THC with nicotine produced behavioral collapse preceded by behavioral disturbance.",
author = "Byron Jones and Consroe, {Paul F.} and Laird, {Hugh E.}",
year = "1976",
month = "1",
day = "1",
doi = "10.1016/0014-2999(76)90327-7",
language = "English (US)",
volume = "38",
pages = "253--259",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The interaction of Δ9-tetrahydrocannabinol with cholinomimetic drugs in an agonist-antagonist paradigm

AU - Jones, Byron

AU - Consroe, Paul F.

AU - Laird, Hugh E.

PY - 1976/1/1

Y1 - 1976/1/1

N2 - In rabbits, i.v. Δ9-tetrahydrocannabinol (Δ9-THC) at 0.5 mg/kg was challenged with i.v. arecoline (0.025 mg/kg), nicotine (0.02 mg/kg) or physostigmine (PHYSO, 0.05 mg/kg), and observations were made on quantified EEG and behavior. The cholinomimetics effectively reversed the cortical and hippocampal EEG alterations induced by Δ9-THC. Arecoline and PHYSO temporarily reversed the behavioral-sedative effects of Δ9-THC whereas the combination of Δ9-THC with nicotine produced behavioral collapse preceded by behavioral disturbance.

AB - In rabbits, i.v. Δ9-tetrahydrocannabinol (Δ9-THC) at 0.5 mg/kg was challenged with i.v. arecoline (0.025 mg/kg), nicotine (0.02 mg/kg) or physostigmine (PHYSO, 0.05 mg/kg), and observations were made on quantified EEG and behavior. The cholinomimetics effectively reversed the cortical and hippocampal EEG alterations induced by Δ9-THC. Arecoline and PHYSO temporarily reversed the behavioral-sedative effects of Δ9-THC whereas the combination of Δ9-THC with nicotine produced behavioral collapse preceded by behavioral disturbance.

UR - http://www.scopus.com/inward/record.url?scp=0017101061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017101061&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(76)90327-7

DO - 10.1016/0014-2999(76)90327-7

M3 - Article

VL - 38

SP - 253

EP - 259

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -